Cart
sales@molnova.com
p38α inhibitor 4
CAS No. 1262406-08-5
p38α inhibitor 4( —— )
Catalog No. M37207 CAS No. 1262406-08-5
p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep38α inhibitor 4
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.
-
Descriptionp38α inhibitor 4 (compound 10) is a selective and allosteric p38α inhibitor with an IC50 value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1262406-08-5
-
Formula Weight347.215
-
Molecular FormulaC14H7F6N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=C(C=2C(=NNC2N1)C=3C=CC=C(C3)C(F)(F)F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. ACS Chem. Biol., Article ASAP
DOI: 10.1021/cb1002619
Publication Date (Web): November 23, 2010
molnova catalog
related products
-
SSK1
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
-
LY2228820 dimesylate
LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
